Drug Royalties Co. Ramps Up Issuance

30 Nov 2012

Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.

Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.

DRI planned to tap the ABS market for financing in August of 2011, but shelved the ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial